
Erratum

**Erratum to: Generic Development of Topical Dermatologic Products:
Formulation Development, Process Development, and Testing of Topical
Dermatologic Products**

Rong-Kun Chang,¹ Andre Raw,^{1,2} Robert Lionberger,¹ and Lawrence Yu¹

Published online 3 September 2015

**Erratum to: AAPS J
DOI 10.1208/s12248-012-9411-0**

The authors inadvertently switched the words “qualitative” and “quantitative” in paragraph two under the header “Formulation Design of Generic Topical Drug Products.” The correct sentence reads as follows:

If feasible, the major formulation goal for a generic topical drug product is qualitative sameness (Q1, same components as the RLD) and quantitative sameness (Q2, same components in same concentration as the RLD, i.e., within $\pm 5\%$) to the RLD [5, 6].

The online version of the original article can be found at <http://dx.doi.org/10.1208/s12248-012-9411-0>.

¹ Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, USA.

² To whom correspondence should be addressed. (e-mail: andre.raw@fda.hhs.gov)